--- title: "Locally Advanced NRG-LU008 | Sutter Health" description: "Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer" url: "https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Locally Advanced NRG-LU008 # Locally Advanced Non-Small Cell Lung Cancer NRG-LU008 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05624996). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or osimertinib) versus the usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be treated by surgery (inoperable).  ![Christopher U Jones, M.D., FACR](https://dyn.mktgcdn.com/p/6fMCH4vO97TB6M5QvU1pl5Qui1fViPD5KLLubfev_dQ/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Christopher U Jones, M.D., FACR Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Locally%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20NRG-LU008%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-early-stage-non-small-cell-lung-cancer-beamion-lung-3-2084403277) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer](https://www.sutterhealth.org/research/clinical-trials/adjuvant-monotherapy-vs-standard-of-care-early-stage-resectable-non-small-cell-lung-cancer-2082765455) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Coming Soon - Clinical trial ### [Adjuvant Non Small Lung Cancer TroFuse-019](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-lung-cancer-trofuse-019-2015848648) A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (MK-2870-019) (TroFuse-019) **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Non-Small Cell Lung Cancer A081801](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-a081801-1049141795) Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-c5851005-padl1nk-005-2064313501) PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Locally Advanced NRG-LU008"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990#medicalwebpage","name":"Locally Advanced Non-Small Cell Lung Cancer NRG-LU008","description":"Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer","url":"https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990#breadcrumblist"},"mentions":[{"@type":"Person","name":"Christopher U Jones, M.D., FACR","url":"https://www.sutterhealth.org/research/investigators/christopher-u-jones-md-facr-1049681071","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990#medicaltrial","name":"Locally Advanced Non-Small Cell Lung Cancer NRG-LU008","alternateName":"Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer","url":"https://www.sutterhealth.org/research/clinical-trials/locally-advanced-nrg-lu008-1049141990","description":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab or osimertinib) versus the usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be treated by surgery (inoperable).","identifier":"NCT05624996","code":{"@type":"MedicalCode","codeValue":"NCT05624996","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT05624996","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Lung Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```